Trial Profile
International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs ELB 139 (Primary)
- Indications Panic disorder
- Focus Therapeutic Use
- Sponsors elbion NV
- 13 Nov 2006 New trial record.